Listed by the USPTO as CANELLA, KAREN A
Tech Center 1600 • Art Units: 1617 1643 1644 1657 1671
This examiner grants 62% of resolved cases
CANELLA, KAREN A is assigned to tech center 1600 and art unit 1617. Across 1142 resolved cases, the allowance rate is 62.3% and the interview lift is 32.8%. The median days to allowance are 1272.
The listed companies are Wisconsin Alumni Research Foundation, Regeneron Pharmaceuticals Inc., and Bms. The listed firms are Fox Rothschild LLP, MBHB - WARF, and MH2 Technology Law Grp. The large case volume provides a substantial basis for planning. The positive interview lift is a prominent feature, supporting deliberate interview preparation alongside claim amendments and written arguments.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17188861 | METHODS FOR IDENTIFYING CHIMERIC ANTIGEN RECEPTOR-TARGETING LIGANDS AND USES THEREOF | Non-Final OA | Massachusetts Institute of Technology |
| 17788993 | INDIVIDUALIZED VACCINES FOR CANCER TREATMENT AND PREVENTION | Non-Final OA | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH |
| 18345385 | Targeted Radiotherapy Chelates for In Situ Immune Modulated Cancer Vaccination | Non-Final OA | Wisconsin Alumni Research Foundation |
| 18182850 | Using Targeted Radiotherapy (TRT) to Drive Anti-Tumor Immune Response to Immunotherapies | Non-Final OA | Wisconsin Alumni Research Foundation |
| 18297451 | TUMOR VACCINATION IN COMBINATION WITH HEMATOPOIETIC CELL TRANSPLANTATION FOR CANCER THERAPY | Non-Final OA | The Board of Trustees of the Leland Stanford Junior University |
| 18095467 | PROTEIN-DRUG CONJUGATES COMPRISING CAMPTOTHECIN ANALOGS AND METHODS OF USE THEREOF | Final Rejection | Regeneron Pharmaceuticals, Inc. |
| 17356497 | TUBULYSINS AND PROTEIN-TUBULYSIN CONJUGATES | Final Rejection | Regeneron Pharmaceuticals, Inc. |
| 18280197 | COMBINATION OF A T CELL THERAPY AND A DGK INHIBITOR | Non-Final OA | Juno Therapeutics, Inc. |
| 18188380 | METHODS AND COMPOSITIONS FOR DOSING IN ADOPTIVE CELL THERAPY | Non-Final OA | Juno Therapeutics, Inc. |
| 18704120 | SUBCUTANEOUS ADMINISTRATION OF CD19-BINDING T CELL ENGAGERS | Non-Final OA | AMGEN RESEARCH (MUNICH) GMBH |
| 18457588 | TGF-B-RECEPTOR ECTODOMAIN FUSION MOLECULES AND USES THEREOF | Non-Final OA | National Research Council of Canada |
| 18354353 | ANTI-CD166 ANTIBODIES, ACTIVATABLE ANTI-CD166 ANTIBODIES, AND METHODS OF USE THEREOF | Non-Final OA | CytomX Therapeutics, Inc. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy62.3% of resolved applications examined by Karen A Canella were allowed (1,142 resolved cases), compared with 34.1% across Art Unit 1617 over the last five years.
This examiner's interview lift is +32.8 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.
Applications allowed by Karen A Canella took 1,272 days on average from filing to allowance.
Karen A Canella examines applications in Art Unit 1617 in Tech Center 1600 (Biotechnology & Pharmaceuticals).
